The Journal of Nuclear Medicine - JNM

Home
United States
Reston, VA
The Journal of Nuclear Medicine - JNM

Founded in 1960, The Journal of Nuclear Medicine is the world’s leading nuclear medicine, molecular i

According to new data announced by Clarivate in the 2020 Journal Citation Reports™ (released in June 2021), JNM ranks third in impact among 134 medical imaging journals worldwide. Impact factor – 10.057
Five-year impact factor – 8.573
Immediacy index – 4.011
Total citations – 32,949
Eigenfactor Score – 0.03249
Article Influence Score – 2.19

12/11/2025

Multicenter, IAEA-supported trial confirms that ⁶⁸Ga-PSMA-11 PET/CT is superior to MRI for primary staging of high-risk and can benefit patients from countries of all income levels. https://ow.ly/pR7x50Xw4pk

12/10/2025

Invited Perspective: SIRPα immuno-PET provides a pan-myeloid view of immune activity during COVID-19. https://ow.ly/OoTS50Xw4qM

12/08/2025

Liquid biopsy is evolving as a promising addition in the evaluation of PSMA radiopharmaceutical therapy. Read more: https://ow.ly/zcIO50Xw4lO

12/05/2025

⁶⁸Ga-PSMA-11 PET tumor volume predicts overall survival of patients with metastatic prostate cancer undergoing taxane-based chemotherapy. https://ow.ly/Kxm050XqJ1b

12/04/2025

Active primary sclerosing cholangitis (PSC) is associated with elevated FAP expression, up to the level of cholangiocarcinoma. FAPI PET/CT may be used for the assessment of PSC activity. https://ow.ly/iSWu50XqIYT

12/03/2025

⁶⁸Ga-RAYZ-8009 demonstrates a favorable biodistribution and dosimetry in patients with hepatocellular carcinoma, offering promising imaging characteristics. https://ow.ly/ZZNS50XqIZW

12/02/2025

Pretherapy ¹²⁴I PET/CT dosimetry shows that metastatic lesions absorb higher radiation doses after thyroid hormone withdrawal than after recombinant human TSH injection. https://ow.ly/T70Y50XqIXB

12/01/2025

HER2-targeted radioimmunotherapy regimen achieves complete and durable response in breast cancer model. https://ow.ly/nCyt50XqIVa

11/28/2025

²¹²Pb-ADVC001 exhibits significant potential and a broad therapeutic window for treating prostate cancer. https://ow.ly/4OgI50XqIU2

11/26/2025

Analysis of tumor changes from the first to the last ¹⁷⁷Lu-PSMA injections through high-speed whole-body 360° ¹⁷⁷Lu CZT SPECT recordings provides strong prognostic information about mCRPC patients. https://ow.ly/lCNP50XqISz

11/25/2025

AI–assisted lesion-tracking analysis of PSMA PET is prognostic for overall survival in patients with mCRPC undergoing PSMA radiopharmaceutical therapy. https://ow.ly/O4sm50XqIMR

11/24/2025

Invited Perspective: ¹⁷⁷Lu-PSMA-617 monotherapy is provocative but no standard of care for metastatic hormone-sensitive prostate cancer. https://ow.ly/FC5i50XqIKo

Address

Reston, VA
20190

Website

http://jnm.snmjournals.org/

Alerts

Be the first to know and let us send you an email when The Journal of Nuclear Medicine - JNM posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Reston?